Federal health officials say they approved a new injectable drug from Human Genome Sciences to treat inhalable anthrax.
The Food and Drug Administration says raxibacumab will provide an alternative to antibiotic drugs that are currently the standard treatment for anthrax infection.
Inhalation anthrax occurs when people breathe in the spores of Bacillus anthracis bacteria. The infection is treated with a 60-day course of antibiotics.
Comments